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Summary
The recent hidradenitis suppurativa (HS) Cochrane review identified outcome
measure heterogeneity as an important issue to address when designing future HS
trials. Our objective was to follow the Harmonising Outcome Measures for Eczema
(HOME) roadmap, by performing a systematic review of HS outcome measure
instruments to inform the development of an HS core outcome set. We performed
a systematic review to identify validation evidence for outcome measure instru-
ments used in HS randomized controlled trials (RCTs), and assessed the method-
ological quality of all HS outcome measure validity studies using the COnsensus-
based Standards for the selection of health Measurement INstruments (COSMIN)
checklist. The 12 RCTs included in the Cochrane review utilized 30 outcome mea-
sure instruments, including 16 physician-reported instruments, 11 patient-
reported instruments and three composite measures containing elements of both.
Twenty-seven (90%) of the instruments lacked any validation data. Two further
instruments have been developed and partially validated. Of the seven studies
meeting our inclusion criteria, six were of ‘fair’ or ‘poor’ methodological quality,
in part because most of the studies were not primarily designed for instrument val-
idation. The HiSCR instrument is supported by good-quality validation data, but
there are gaps, including assessment of internal consistency, inter-rater reliability
and minimal clinically important difference, and convergent validity fell below the
acceptable range for some comparisons. Multiple, usually unvalidated, outcome
measure instruments have been used in HS RCTs. Where validation evidence is
available there are issues of low methodological quality or incomplete validity
assessment and so, currently, no instruments can be fully recommended.
What’s already known about this topic?
• The recent hidradenitis suppurativa (HS) Cochrane review identified heterogeneity of
outcomemeasure instruments as an important obstacle in the design of future HS trials.
• The Harmonising Outcome Measures for Eczema (HOME) initiative provides a
roadmap for developing a core outcomes set in HS.
What does this study add?
• Twenty-seven of the 30 outcome measure instruments used in HS randomized con-
trolled trials are not supported by any formal validation data.
• Where available, validation evidence is generally of relatively low methodological qual-
ity, or remains incomplete, and so no instruments can be fully recommended currently.
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Hidradenitis suppurativa (HS), also known as acne inversa, is
a chronic painful inflammatory skin disease affecting about
1% of the European adult population.1,2 Despite being a rela-
tively common disease, there is a lack of high-quality HS clini-
cal trials, confirmed by a recent Cochrane review of both
medical and surgical HS interventions, which was able to
include only 12 randomized controlled trials (RCTs).3 The
authors of the review concluded that more HS RCTs are
required, to increase the HS evidence base and improve
patient care; however, it was also noted that many different
outcome measures had been used in the trials. Outcome mea-
sure heterogeneity did not have a significant impact on the
Cochrane review in terms of meta-analyses involving direct
comparisons as only two RCTs investigated the same interven-
tion. However, indirect comparisons were prevented and the
heterogeneity is likely to have a greater impact on updates of
the Cochrane review, when more trials have been published
and larger meta-analyses may be possible. In addition, inter-
pretation of the results of the review was hampered by many
of the instruments lacking validation data to confirm that
results were clinically meaningful, valid and reliable.
Clinical trial research in HS has therefore reached an impor-
tant stage where there is an opportunity to establish a consensus
regarding which outcome measures should be used and to
determine whether further instrument validation studies are
needed. Lessons from the Harmonising Outcome Measures for
Eczema (HOME) initiative, conducted to ensure that future
eczema clinical trials incorporate a core outcome set, demon-
strate that outcomes consensus is best conducted prior to clinical
trials being instigated.4 The HOME roadmap sets out a method-
ological framework for developing outcomes consensus.4 Once
the medical condition and the potential interventions have been
defined, a core set of outcome domains is identified, encom-
passing the relevant range of outcomes from both a patient and
clinician perspective. A systematic review of outcome measure
instruments is required to generate a long list of the instruments
currently available within each domain and to assess the extent
and quality of the validation evidence in each case, which is the
aim of the current review. A consensus process can then be
employed to determine whether HS outcome domains can be
accurately assessed by current instruments, or whether further
validation data or new instruments are required.
Materials and methods
Long list of outcome measure instruments
Generation of a long list of outcome instruments is based
on the Cochrane review of ‘Interventions for hidradenitis
suppurativa’. The methodology employed by the Cochrane
review is published elsewhere and, briefly, involved searches
in MEDLINE, Embase, LILACS, the Cochrane Skin Group
Specialised Register, and Cochrane Central Register of Con-
trolled Trials (CENTRAL), from inception until August
2015, for all RCTs conducted in adults with HS.3 Searches,
with the same final search date, were also conducted in five
trial registries and the proceedings of eight dermatology
conferences. Abstract screening and data extraction were per-
formed by two authors working independently. All of the
instruments contained within the included RCTs were docu-
mented by the current study’s authors, including details of
the items contained in the scale and the range of possible
values.
Search for instrument validation data
MEDLINE and Embase were searched from inception to
November 2015 for varying combinations of the subject terms
‘hidradenitis suppurativa’, ‘acne inversa’, ‘severity’ and ‘sever-
ity of illness index’, using similar search terms to Schmitt
et al.5 The reference lists of relevant articles were also
searched, in addition to performing a separate free internet
search for HS psychometric data. No language restrictions
were applied, but the literature search was limited to articles
with abstracts involving at least five human participants and
containing original data. Two authors (J.R.I. and S.H.) inde-
pendently screened the abstracts and full texts for eligibility,
and data extraction was also performed by the two authors
independently. Disagreements were resolved by discussion
between the authors. Articles were included if they contained
evidence pertaining to at least one of validity (content, con-
vergent, divergent); reliability (internal consistency, interob-
server reliability, test–retest reliability); interpretability
[sensitivity to change, minimal clinically important difference
(MCID), clinical severity banding]; or feasibility (time taken)
of a HS outcome measure instrument. For each scale quality
criterion we assigned a rating of ‘acceptable’ or ‘adequate’,
based on parameters set out in a previous systematic review of
eczema outcome measure instruments that informed the
HOME consensus process.5 For example, in the case of con-
vergent validity, a correlation coefficient of 060–069 was
designated ‘acceptable’, while a coefficient > 070 was
deemed ‘adequate’.
We repeated our searches for HS instrument validation
studies in MEDLINE and Embase using the sensitive search
filter developed by the COnsensus-based Standards for the
selection of health Measurement INstruments (COSMIN)
group, which has a sensitivity of 974%.6 No additional HS
instrument validation studies were identified from the extra
searches.
Assessment of methodological quality of included
studies
Methodological quality of the included studies was assessed
using the COSMIN checklist.7 The checklist applies a four-point
rating scale of ‘excellent’, ‘good’, ‘fair’ or ‘poor’ for each mea-
surement property, based on the lowest rating for each item
assessed, including handling of missing data, adequate sample
size and appropriate statistical analysis. Two authors (J.R.I. and
S.H.) independently assessed methodological quality and
resolved any differences by subsequent discussion.
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Results
Outcome instruments included in Cochrane review
studies
The 12 RCTs included in the HS Cochrane review contained a
total of 30 outcome measure instruments, including 16 physi-
cian-reported instruments, 11 patient-reported outcomes and
three composite measures containing elements of both
(Table 1).8–20 Grouping the instruments in terms of potential
outcome domains, six of the physician-reported instruments
involved a skin lesion count;8–13 five were based on a physi-
cian’s global assessment (PGA);13–17 one assessed recurrence
rate;18 one measured cosmesis;8 one examined duration of
recovery from surgical treatment;18 and two contained ele-
ments of the PGA combined with either a measure of cosmesis
or a lesion count.7,12 Of the 11 patient-reported outcome
measure instruments, four involved a patient global self-
assessment;13–15,19 two measured overall satisfaction with
treatment;9,20 two measured pain;8,12,13,15,16 one used a
patient lesion count;8 one was a quality-of-life scale;8,12,15,16
and one measured impairment of function.12
In several cases, particularly within the lesion count
domain, there were a number of closely related instruments,
often involving modification of a previously published instru-
ment. For example, the lesion count score published by Sarto-
rius et al. in 2003 has been modified to produce five different
instruments, including a modification by the original authors
in 2009.21,22 In some cases, the instrument was modified to
permit a within-participant trial design in which each region,
rather than the whole individual, is given a severity score.9,10
Each instrument contains different items and so, although
there is quite a lot of overlap between the instruments, their
scores cannot be directly compared in meta-analyses. The
potential for confusion is confounded by different names
being assigned to the same outcome instrument. In particular,
the instrument published by Sartorius et al. in 2009 was
named the ‘modified HS Score (modified HSS)’ in the arti-
cle,22 but the name ‘modified Sartorius Score’ (MSS) has been
used subsequently in several publications, and ‘HS-LASI’ (‘HS
lesion, area, and severity index’) has also been used as another
alternative name.
Instruments supported by validation data
Our search for instrument validation data identified 119
abstracts, of which 112 were excluded owing to a lack of
our prespecified validation evidence (Fig. 1). The seven
included studies relate to six outcome measure instruments,
two of which, the Hidradenitis Suppurativa Clinical Response
(HiSCR) and Acne Inversa Severity Index (AISI),23,24 have
only been published recently and have not yet been used in
an RCT (Table 2). The HiSCR instrument was developed ret-
rospectively from an RCT that used other outcome measures
in the trial itself.12 The HiSCR measure is designed to assess
treatment response in a binary manner, rather than being a
continuous or ordinal scale. It fits within the lesion count
outcome domain, involving a count of the total number of
abscesses and inflammatory nodules, designated ‘ANs’, as
well as recording the number of sinuses draining purulent
fluid present in an individual.23 Treatment responders are
defined as those who achieve at least a 50% reduction in
ANs, with no increase in the number of abscesses or drain-
ing sinuses, relative to baseline. Because the instrument
involves a percentage decrease in ANs, the patient population
for the validation sample was limited to those with at least
three ANs, to ensure that a reduction of one AN does not
achieve the end point.
The AISI outcome measure is a composite instrument
recently designed by a group of clinicians in Italy incorporat-
ing a physician-reported lesion count and a patient-reported
visual analogue scale (VAS) measure of pain and disability.24
The instrument designers assigned a score for each type of HS
lesion (comedones, abscess/inflammatory nodule, sinus tract,
keloid/fibrotic adherence, fibrosclerotic inflammatory plaque
are scored 1, 2, 3, 4 or 5 points, respectively), which is then
multiplied by the number of body sites where the lesion
occurs (rather than the number of lesions observed). The
score from 0 to 10 from the combined pain and disability
VAS is then added to produce a final total. So far, one valida-
tion study has been performed in 46 patients with HS attend-
ing a secondary care dermatology clinic.24
Validation data and assessment of methodological
quality of the studies
Despite the Hurley scoring system being one of the most rec-
ognized HS disease severity instruments,25 very little formal
outcome measure validity data are available. One recent study
examining quality of life in HS provides divergent validity
data in comparison with Dermatology Life Quality Index
(DLQI) scores.26 A correlation coefficient of 0549 is reported;
however, methodological quality was downgraded to ‘fair’
because it was not clear how missing items were handled
(Table 2).
Two studies containing a total of 176 patients provide vali-
dation evidence for the MSS.22,27 The Spearman rho correla-
tion coefficient measuring divergent validity compared with
DLQI scores was found to be 0342 in one study and 048 in
the other (Table 2).22,27 Methodological quality was down-
graded to ‘fair’ in each case because it was not clear how
missing items were handled. The correlation coefficient for
interobserver reliability was 095, indicating that this criterion
was met adequately.27 However, methodological quality was
downgraded to ‘poor’ because, while 61 patients took part in
some aspects of the study, only 23 patients were rated by
more than one dermatologist independently.
An epidemiology study examining 302 patients with HS
provides some convergent validity data between the Revuz
version of the original Sartorius Score and the Hurley stage
and degree of suppuration.28 However, the study was not pri-
marily designed to provide HS outcome measure validation
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Table 1 Outcome measure instruments used in randomized controlled trials of interventions for hidradenitis suppurativa (HS)
Instrument Potential domain Range Description Trial reference
Physician reported
Hurley stage25 Lesion count I–III (worst) Stage I: single or multiple abscesses without
sinus tracts or scarring; stage II: recurrent,
widely separated abscesses with sinus tracts
and scarring; stage III: multiple
interconnected sinus tracts and abscesses
across entire region
Miller et al.8
Original version of
Sartorius Score21
Lesion count 0–unlimited (worst) Three points are assigned for each involved
region and each scar, nodule and sinus are
scored 1, 2 and 4 points, respectively; for
each affected region, six points are added
for lack of normal skin between lesions
and the greatest distance between lesions is
scored 2, 4 and 8 points for < 5 cm, 5–
10 cm and > 10 cm, respectively
Miller et al.8
Highton version of
Sartorius Score
Lesion count 0–unlimited (worst) Each scar, nodule and sinus scored 1, 2 and
4 points, respectively; for each affected
region, degree of erythema and discharge
scored 0–3, 6 points are added for lack of
normal skin between lesions, and the
greatest distance between lesions is scored
2, 4 and 8 points for < 5 cm, 5–10 cm
and > 10 cm, respectively
Highton et al.9
Tierney version 1 of
Sartorius Score
Lesion count 0–unlimited (worst) For a particular region, each scar, abscess,
nodule and fistula are scored 1, 1, 2 and 4
points, respectively; 6 points are added for
lack of normal skin between lesions and
the greatest distance between lesions is
scored 2, 4 and 8 points for < 5 cm, 5–
10 cm and > 10 cm, respectively
Tierney et al.10
Modified Sartorius Score
(Sartorius 2009)22
Lesion count 0–unlimited (worst) Three points per region of involvement, 1
point per nodule, 6 points per fistula,
Hurley III 9 points per region; greatest
distance between two lesions in each
region: < 5 cm, 1 point, 5–10 cm, 3
points, > 10 cm, 9 points
Fadel and Tawfik,11
Kimball et al.12
Abscess and nodule count Lesion count 0–unlimited The number of nodules and abscesses are
each counted
Kimball et al.,12
Jemec and
Wendelboe13
HS-PGA PGA/lesion count Clear–very severe Ordinal scale: clear, minimal, mild,
moderate, severe, very severe; based on
total number of abscesses, fistulas,
inflammatory and noninflammatory
nodules
Kimball et al.12
Mortimer PGA scale PGA +9 to 6 (worst) Relative to baseline, changes in disease
activity are scored as clear (+3), much
improved (+2), improved (+1), unaltered
(0), worse (1) and much worse (2) for
each of the number of inflamed/
noninflamed nodules, degree of induration
and tenderness, and presence of draining
sinuses
Mortimer et al.14
SGA PGA 0 (clear)–3 (severe) SGA is a mean score derived from three
domains: tenderness on palpation,
erythema of lesions, and discharge, each
measured from 0 to 3
Adams et al.15
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Table 1 (continued)
Instrument Potential domain Range Description Trial reference
PGA PGA Cleared to worse 7-point ordinal scale relative to baseline
severity (% improvement): cleared
(100%), excellent (75–99%), good (50–
74%), fair (25–49%), slight (1–24%),
unchanged, worse
Grant et al.16
PGA scale PGA Improved, same,
worse
Ordinal scale with three levels for change
from baseline in terms of ability of lesions
to drain spontaneously without surgery
and number of acute inflammatory lesions
Angel et al.17
Physician global evaluation PGA 0–100 (worst) VAS Jemec and
Wendelboe13
PGA scar scoring Cosmesis/PGA ND ND Miller et al.8
Manchester Scar Proforma33 Cosmesis Higher score worse Scar number, size, margins, surface, colour
and texture are used to compile a score
Miller et al.8
Local recurrence rate Recurrence rate 0–100% (worst) Recurrence at surgical site following surgery
(no specified maximum distance from
scar)
Buimer et al.18
Time to complete wound
healing
Duration of recovery 0–no limit Time of complete wound healing in days Buimer et al.18
Patient reported
Patient global assessment
of HS lesions
Patient global
self-assessment
0–5 (severe) Ordinal scale from 0 (good) to 5 (severe) Adams et al.15
Patient global assessment
VAS
Patient global
self-assessment
0–100 (worst) VAS Jemec and
Wendelboe13
Change in patient global
assessment VAS
Patient global
self-assessment
0–100 (better) Baseline disease severity defined as a score
of 50; a score of 100 denotes ‘completely
better’ and 0 denotes ‘worst it has ever
been’
Mortimer et al.14
Patient global assessment Patient global
assessment
2 to +2 (better) Ordinal scale relative to baseline severity:
+2, much improved, +1,
improved, 0, unaltered, 1, worse,
2, much worse
Clemmensen19
Treatment satisfaction Overall satisfaction Excellent to worse Likert scale relative to baseline: excellent,
good, fair, unchanged, worse
Highton et al.9
Treatment satisfaction
questionnaire
Overall satisfaction ND Recorded patients’ views of treatment
benefit both in absolute terms and relative
to other interventions, adverse effects of
therapy and overall satisfaction
Mahmoud et al.20
Pain Pain 0–5 (severe) Ordinal scale from 0 (none) to 5 (severe) Adams et al.15
Pain VAS Pain 0–100 VAS Miller et al.,8
Kimball et al.,12
Jemec and
Wendelboe,13
Grant et al.16
Patient report of lesions Lesion count 0–unlimited (worse) Patient report of number of days with active
lesions between clinician reviews
Miller et al.8
DLQI Quality of life 0–30 (worst) 10 quality-of-life domains scored from 0
(no effect) to 3 (very large effect)
Miller et al.,8
Kimball et al.,12
Adams et al.,15
Grant et al.16
TWPI score Impairment of
function
0–100 (worst) Score obtained from WPAI-SHP
questionnaire
Kimball et al.12
Composite scales
HSSI Lesion count and
pain
0–19 (worst) 0–4 points for each of number of affected
regions, BSA involved, number of active
lesions, number of dressing changes per
day, pain VAS score
Grant et al.16
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data and methodological quality was downgraded to ‘poor’
owing to use of linear regression rather than calculation of
correlations or the area under the receiver operating curve.
An RCT of intense pulsed light for HS used the Highton
version of the original Sartorius score and calculated a kappa
statistic of 079 for inter-rater reliability.9 Methodological
quality was graded ‘poor’ because only 17 participants took
part in the trial.
For the HiSCR instrument, acceptable convergent validity
was met with regard to a PGA (correlation coefficient 061),
while the correlation coefficient was below this level when
compared with the Hurley Stage and MSS (coefficients of 049
and 051, respectively).23 As expected, correlation was lower
when compared with patient-reported outcome scores because
these measure different constructs. Methodological quality was
downgraded from ‘excellent’ to ‘good’ because, while the
method for dealing with missing items was described in the
original RCT publication, the percentage of missing items was
not explicitly stated in the context that not all of the RCT par-
ticipants were included. Test–retest reliability for HiSCR was
adequate for both ANs and sinuses, with intraclass correlations
of 091 and 095, respectively, and methodological quality
was again rated ‘good’. Using the original trial data,12 more
patients reached the threshold for improvement compared
Table 1 (continued)
Instrument Potential domain Range Description Trial reference
Cumulated score Lesion count and
patient global
self-assessment
Negative or positive
(better), with no
limit
Relative to baseline, 5 points assigned to
each inflammatory nodule, abscess and
change of one level in the patient global
assessment scale, 1 point assigned to each
pustule (for lesions, a positive score
indicates resolution, while a negative score
denotes a new lesion)
Clemmensen19
Tierney version 2 of
Sartorius 2003
Lesion count and
pain
0–unlimited (worse) For a particular region, each scar, abscess,
nodule and fistula are scored 1, 1, 2 and 4
points, respectively; 6 points are added for
lack of normal skin between lesions and
the greatest distance between lesions is
scored 2, 4 and 8 points for < 5 cm, 5–
10 cm and > 10 cm, respectively; up to 3
points are scored for each of erythema,
oedema, pain and purulent discharge
Tierney et al.10
PGA, physician’s global assessment; SGA, static global assessment; VAS, visual analogue scale; ND, no details; DLQI, Dermatology Life Quality
Index; TWPI, Total Work Productivity Impairment; WPAI-SHP, Work Productivity and Activity Impairment – Specific Health Problem; HSSI,
HS Severity Index; BSA, body surface area.
94 articles from PubMed 22 additional articles from 
Embase
3 additional articles from 
reference lists
119 abstracts reviewed
13 full manuscripts 
reviewed
7 articles included
106 excluded owing to lack 
of validation data
6 excluded owing to lack 
of validation data
Fig 1. Validation studies included.
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with the HS-PGA instrument;29 however, a correlation coeffi-
cient was not calculated and so the sensitivity to change of
HiSCR requires further evaluation.
The AISI instrument demonstrated adequate convergent
validity with Hurley stage and the Revuz version of the Sarto-
rius 2003 score (correlation coefficients of 071 and 097,
respectively).24 In terms of divergent validity, correlation with
DLQI scores was relatively high but still within the acceptable
range (with a coefficient of 083). Methodological quality for
the validity assessments was downgraded to ‘fair’ owing to
inadequate information regarding the handling of any missing
items. The authors also used the distribution of AISI scores to
determine three disease severity bands corresponding to mild,
moderate and severe disease. The time required to complete
the AISI score was about half that needed for the Revuz score
(464 vs. 832 s).24
Across all seven studies, there was an absence of data cover-
ing the criteria of content validity, internal consistency and
MCID.
Discussion
Our results confirm that outcome measure heterogeneity is a
problem for HS research, with 30 instruments used in the 12
RCTs included in the HS Cochrane review, and will become an
increasing problem if an outcomes consensus process is not
undertaken in the near future. Of note, 27 of the 30 outcome
measure instruments employed in HS RCTs to date have no val-
idation data to support their use, representing 90% of the total.
Seven papers were found to provide some validation data, but,
in general, their methodological quality was relatively low.
Using the COSMIN checklist, six of the seven studies were
graded as ‘fair’ or ‘poor’ in quality, in part because instrument
validation was not the primary purpose of the research.
Good-quality validation evidence is available for the recently
described HiSCR instrument, which has acceptable convergent
validity with the PGA and adequate test–retest reliability.
However, the correlation coefficient falls below the acceptable
range for comparisons with the MSS and Hurley staging. In
addition, internal consistency, inter-rater reliability and MCID
have not been assessed yet and so further evidence is still
needed.
In some of the validation studies examined, confusion was
apparent in the criteria of convergent and divergent validity.
For example, some studies have compared a scale in the lesion
count domain with a quality-of-life instrument to attempt to
demonstrate convergent validity, which is comparing two dif-
ferent disease severity constructs and so instead falls within
the divergent validity category. The relatively high correlation
coefficient between AISI and the DLQI scale may, in part, be
explained by inclusion of pain and disability, as well as a
lesion score, in the AISI instrument, items that are also mea-
sured by the DLQI.
Our results are broadly in keeping with the findings of sys-
tematic reviews conducted for eczema outcome measures, to
inform the HOME consensus process. In 2003, only 27% of
eczema trials used a previously published severity scale and,
from the 93 trials included, 56 different objective scoring sys-
tems were identified.30 Assessment of validation data for
eczema outcome measure instruments in 2007 found that only
three instruments had undergone sufficient validation to rec-
ommend their use in trials and routine practice.5
One of the strengths of our systematic review is that we
predefined ‘acceptable’ and ‘adequate’ parameters for each
quality criterion relevant to assessment of measurement instru-
ments. In addition, we assessed the methodological quality of
the validity studies identified using the COSMIN checklist.
These assessments will be helpful to inform the subsequent
outcome measures consensus process. Our review of HS out-
come measure instruments has been performed earlier in the
research cycle than atopic eczema, at a time when fewer HS
trials have been conducted. Hence, one limitation of our
review is that it contains relatively few validation studies. It
may be that the subsequent consensus process will have to
identify and commission further validation studies for pre-
existing instruments or recommend development of new
instruments.
Our review has identified 10 potential efficacy outcome
measure domains: quality of life; pain; lesion count; PGA;
patient global self-assessment; recurrence rate; overall satisfac-
tion with treatment; impairment of function; cosmesis; and
duration of recovery. Most domains are relevant to both med-
ical and surgical interventions. However, recurrence rate and
duration of recovery are more specific for surgical treatments
in the context that some procedures, such as extensive exci-
sion, aim to provide disease remission in the treated region,
at the expense of prolonged wound healing. The subsequent
consensus process will need to define the outcome domains
in more detail, incorporating the views of all relevant
stakeholders, namely patient representatives, dermatologists,
surgeons, primary care physicians, regulatory authorities
and journal editors, with predetermined definitions of
consensus.31
Support from international dermatology outcomes consor-
tia, such as the Cochrane Skin Group Core Outcomes Set
Initiative (CSG-COUSIN) and the International Dermatology
Outcome Measures (IDEOM) group has been sought, to
ensure that the planned consensus process has a broad geo-
graphical base and methodological rigour. Several challenges
are likely to be encountered in terms of scope, outcome
domains and instrument validation. Regarding the scope of
the process, debate will be needed as to whether medical and
surgical interventions require separate outcome domains and,
if so, into which category laser and light interventions should
be placed. When defining recurrence rate as a potential
domain, care will be required to determine whether recur-
rence is defined as any new HS lesions within a previously
treated region, or whether only those lesions within a certain
distance from the scar or treatment area should qualify. The
domain of ‘lesion count’ may need broadening from the cur-
rent paradigm, which is generally restricted to counting
lesions at particular predetermined time points, potentially
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missing menstrual or other exacerbations between clinician
visits. The HOME group has agreed that long-term control of
flares should be one of the core outcome domains in atopic
eczema,31 and it may be that the frequency of new lesions or
recurrent activity in scar sites from previous lesions should be
considered as a new outcome domain of ‘flare frequency’ in
HS. Any new domain will, of course, require development
and validation of new measurement instruments.
In summary, our systematic review of HS outcome measure
instruments has demonstrated substantial heterogeneity, rein-
forcing the need for a consensus process. Ninety percent of
the instruments that have been used in HS RCTs lack any vali-
dation evidence and most of the evidence that is available is
of relatively low methodological quality. More validation stud-
ies are required to ensure that HS outcome measure instru-
ments can satisfy the Outcome Measures in Rheumatology
(OMERACT) filter,32 which is designed to assess ‘truth’, ‘dis-
crimination’ and ‘feasibility’.
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